Clinical Trials Logo

Pancreatitis clinical trials

View clinical trials related to Pancreatitis.

Filter by:

NCT ID: NCT02079363 Recruiting - Clinical trials for Pancreatic Neoplasms

DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer

Start date: August 2013
Phase: N/A
Study type: Observational

The objectives of this project are to test whether alteration in DNA hypermethylation in plasma is: - a diagnostic marker for pancreatic cancer - a prognostic marker for pancreatic cancer - a marker for recurrence of pancreatic cancer - changing during the course of chronic pancreatitis, with the purpose of finding patients with high risk of developing pancreatic cancer

NCT ID: NCT02078245 Recruiting - Clinical trials for Hereditary Pancreatitis

Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.

Start date: August 2010
Phase:
Study type: Observational [Patient Registry]

Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer. In this study, following the indication of the swedish guidelines, consecutive patients with a family history for pancreas cancer underwent a clinical surveillance Magnetic Resonance Imaging (MRI) based. The results of this study were analyzed looking in the patients files collected during the screening period.

NCT ID: NCT02054910 Recruiting - Clinical trials for Small Duct Chronic Pancreatitis

CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis

Start date: October 2013
Phase: N/A
Study type: Interventional

This study assesses the pain response to Endoscopic Ultrasound (EUS) guided Celiac Plexus Block (CPB) treatment in comparison to EUS without a pain block administered. All participants will receive medications for pain as needed.

NCT ID: NCT02050048 Terminated - Pancreatitis Clinical Trials

High Volume Lactated Ringer's Solution and Pancreatitis

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to examine whether giving large amounts of intravenous (IV) fluids will reduce the risk of developing a complication known as post-ERCP pancreatitis (PEP). Pancreatitis is inflammation of the pancreas, and it is the most frequent serious complication of ERCP. Typically, a small amount of IV fluids are given during this procedure (~ 1 liter). We are testing whether using a larger amount of fluids (2 - 3 liters) will reduce the risk of PEP.

NCT ID: NCT02048267 Completed - Clinical trials for Pancreatitis, Chronic

Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis

Start date: January 2012
Phase: N/A
Study type: Observational

Numerous treatment modalities have been proposed to treat pain in alcoholic and non-alcoholic chronic pancreatitis such as analgesic medication, inhibition of gastric acid production, enzyme substitution, somatostatin analogues, nerve blockade,reduction of oxidative stress and endoscopic pancreatic duct stenting, but none of these concepts have shown long lasting benefits as surgery in clinical studies.Comparison of surgical outcome in non-alcoholic chronic pancreatitis and alcoholic chronic pancreatitis has limited data and differences on the basis of outcome in between alcoholic and non-alcoholic chronic pancreatitis are not available in literature. Although it is well known that pain is the main symptom of chronic pancreatitis, it has until now been assessed in very common and varying categories. Pain, however, is only one aspect of the large variety of sensitive facets of daily life. In addition to an improvement in pain symptoms and the preservation of pancreatic exocrine and endocrine function and other parameters, occupational rehabilitation of these mostly young patients and quality of life also should be considered in the evaluation of surgical outcome in alcoholic and non-alcoholic chronic pancreatitis. In this prospective study, we intend to find out if there are any differences in the surgical outcome on the above mentioned parameters in alcoholic and non-alcoholic chronic pancreatitis.We also plan to see if there are differences in the histopathology in these two disease settings.

NCT ID: NCT02027311 Completed - Pancreatic Cancer Clinical Trials

Etomidate vs. Midazolam for Sedation During ERCP

Start date: April 2013
Phase: Phase 4
Study type: Interventional

Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system. The investigators are now trying to investigate that etomidate with meperidine combination regimen is superior to the midazolam with meperidine more effective and less harm on sedation during the ERCP procedure.

NCT ID: NCT02025049 Terminated - Pancreatitis Clinical Trials

DP-b99 in the Treatment of Acute High-risk Pancreatitis

Start date: December 2013
Phase: Phase 2
Study type: Interventional

Inflammation of the pancreas often leads to severe damage not only to the pancreas but also to other organs in the abdomen as well as to complications in organs further away like the lung and the kidney. This trial will examine if DP-b99, given to patients with non-severe inflammation of the pancreas, can mitigate the development of processes that can lead to serious complications of this disease.

NCT ID: NCT02002793 Recruiting - Pancreatitis Clinical Trials

Effects of Early Stage Mini-invasive Abdominal Drainage on Complications and Prognosis of SAP

Start date: August 2013
Phase: N/A
Study type: Interventional

This study aims to standardized the process of mini-invasive abdominal draniage of SAP in early stage.To determine the indications and occasion.

NCT ID: NCT02002650 Completed - Clinical trials for Post-ERCP Acute Pancreatitis

Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Indomethacin
Start date: December 2013
Phase: N/A
Study type: Interventional

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. A number of trials have evaluated that rectal NSAIDs (non-steroidal anti-inflammatory drug) can prevent post-ERCP pancreatitis (PEP) in high risk patients. However, the risk factors of PEP is not fully clear. Rectal indomethacin before ERCP for all patients, not just for selected high-risk factor patients, may preventing the PEP maximum. The purpose of this study is to determine whether routine using of rectal indomethacin is more effective than the conditional regimen.

NCT ID: NCT02000999 Completed - Pancreatic Cancer Clinical Trials

Diagnosis of Bile Duct Strictures

Start date: November 2013
Phase:
Study type: Observational

The purpose of this prospective study is to compare the diagnostic utility of two techniques (brush cytology + FISH and brush cytology + free DNA analysis) in the diagnosis of biliary strictures. Histologic diagnosis (biopsies) in conjunction with clinical and/or imaging follow-up will serve as the gold standard for diagnosis of malignancy. In order to do this the investigators will ask study participants to have a small volume of fluid obtained from the bile duct sent for additional testing at RedPATH. In some patients additional brushings will be obtained for FISH testing (this adds <2 minutes to ERCP and only associated risk is increased procedure duration). The investigators hypothesize that the use of cytology +DNA analysis has a higher sensitivity and accuracy when compared to cytology +FISH in patients with biliary strictures. Primary aim: To compare the sensitivity and accuracy of the two techniques (brush cytology + FISH and brush cytology + free DNA analysis). Histologic diagnosis (histology from biopsy or cytology for fine needle aspiration) in conjunction with clinical and/or imaging follow-up will serve as the gold standard for diagnosis of malignancy. Secondary aims: 1. To evaluate the diagnostic yield of malignancy when all three techniques (cytology, FISH and DNA analysis) are used. 2. To evaluate the added value of biliary forceps biopsies, when used in conjunction with cytology, FISH and DNA analysis.